

Press release

March 12th, 2007

Further information

Prof. Dr. Harald Mischak
CSO
Phone: +49 (0)511 55 47 44 13
Fax: +49 (0)511 55 47 44 31
mischak@mosaiques-diagnostics.com

Dr. Harald-Gerhard Geppert
Director Therapeutic & Clinical
Applications
Phone: +49 (0)511 55 47 44 23
Fax: +49 (0)511 55 47 44 31
geppert@mosaiques-diagnostics.com

**mosaiques diagnostics &
therapeutics AG**
Mellendorfer Straße 7-9
D-30625 Hannover
GERMANY
www.mosaiques-diagnostics.com

Tracing kidney diseases

Fast and accurate detection of kidney diseases – The DiaPat® technology revolutionises the examination of the renal system

Hannover - 180 millions people suffer from diabetes worldwide and this number will duplicate to 370 millions till 2030 (WHO). These are alarming figures already today for the health systems of Europe. Further, renal and cardiovascular diseases are the most serious consequences of diabetes, and represent the largest share of annual health-care costs in Europe. The evident *disease-induced collapse* of the national economies can only be prevented by a reliable preventive medical examination.

Renal diseases are diagnosed too late, as impairments of the organ are not immediately apparent due to pain or other alarming symptoms. Affected persons are not aware of the risks or the existing disease. Education and precaution is desperately needed. The necessity of surveys for the early diagnosis becomes more and more evident and leading clinicians demand mandatory preventive medical examination starting at an age of 45-50. A non invasive preventive medical examination, as was developed by mosaiques diagnostics and therapeutics AG, is the ideal diagnostic method to meet these requirements.

The mosaiques diagnostics & therapeutics AG (Hannover), a pioneer in the field of clinical proteome analysis, published a review article in the leading Journal of the American Society of Nephrology (Issue April 2007) together with seven renowned scientists from international leading research institutes. The article *Advances in Urinary Proteome Analysis and Biomarker Discovery* describes the enormous possibilities and advantages of proteome analyses for the diagnosis of renal diseases. "We are able to detect over 80% of all chronic renal diseases plus the progression of diabetic nephropathy up to five years in advance. Furthermore, we are in the position to

detect cardiovascular diseases with very high accuracy”, commentates Prof. Dr. Harald Mischak, founder and CSO of the mosaiques diagnostics & therapeutics AG, the background of this important publication.

The mosaiques diagnostics & therapeutics AG focused its development on the fact that proteins rule life of all organisms. Proteins are indispensable for the function of cells and organs, as well as for all communication inside the body. They catalyse chemical reactions and protect the body against pathogens. Thousands of proteins are involved in these processes, forming a distinct pattern, which changes with disease. The company from Hannover is worldwide the only one capable of detecting these patterns and interpreting them for the diagnosis of several diseases. Utilizing their patented DiaPat® (**diagnostic pattern**) technology, mosaiques diagnostics & therapeutics AG can detect renal and urogenital diseases with high accuracy, even before clinical symptoms are evident. Mosaiques was supported by the BioRegion (Hannover) and grants from the Federal Ministry of Education and Research (BMBF) and the federal state of Lower Saxony. The patented platform technology enables diagnosis, assessment of disease progression and evaluation of therapy and therapeutics. Since 2005 the mosaiques AG markets the early and differential diagnosis of diseases via their subsidiary DiaPat GmbH with constantly increasing success.

About mosaiques diagnostics & therapeutics AG

The mosaiques diagnostics & therapeutics AG was founded in 2002 in Hanover (Germany). The company’s core competence is the early and reliable detection of diseases based on fast and accurate analysis of proteins and polypeptides in urine utilising diagnostic patterns (DiaPat). Diagnosis of bladder and prostate cancer, chronic renal diseases, diabetic nephropathy, graft versus host disease, ureteropelvic junction obstruction in newborn and infarct risk is already marketed through the subsidiary DiaPat GmbH. The mosaiques diagnostics & therapeutics AG also performs clinical trials with the pharmaceutical industry that enable improvement of therapy and therapeutics, based on the individual molecular polypeptide signature.